FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Described is a group of inventions comprising a humanised monoclonal antibody or antigen-binding fragment thereof which binds to specificity with the Thomsen-Friedenreich antigen (TF-Ag), a conjugate binding to cancer cells which express TF-Ag, method for preventing or treating cancer in an individual, wherein the cancer contains TF-Ag-expressing cancer cells, a pharmaceutical composition for treating TF+ cancer types containing said antibody or antigen-binding fragment thereof in a therapeutically effective amount, a mammalian host cell for expressing said antibody or antigen-binding fragment thereof. In one embodiment of the invention, said antibody contains a constant region of human IgG.
EFFECT: presented invention extends the range of products for binding with Thomsen-Friedenreich antigen.
7 cl, 7 tbl, 13 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| IL2 ANTIBODIES | 2006 |
|
RU2425054C2 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| "ANTIBODY-DRUG" CONJUGATES | 2012 |
|
RU2624141C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
| ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| HUMANISED ANTIBODIES TO LIV-1 AND USE THEREOF FOR TREATING CANCER | 2011 |
|
RU2608646C2 |
